Category: Trick or Trade

Agenus Strategic Decision to Withdraw the BLA for Balsitilimab

Agenus to Withdraw BLA for Balstilimab Agenus (AGEN) announced a strategic decision to withdraw its Biologics License Application (BLA) for balstilimab, its PD-1 inhibitor. The firm stated that its decision will not change the development plans for balstilimab with regard to its combination with AGEN1181, which will be launched in multiple tumor types. Following the full approval of pembrolizumab, which was announced four months earlier …

The Time Has Come to Present Mirum Pharmaceuticals Inc

Mirum Pharmaceuticals Inc Mirum Pharmaceuticals Inc (MIRM) is a clinical-stage biopharmaceutical company focused on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. Maralixibat, is Mirum Pharmaceuticals lead product candidate. The product is an investigational oral drug in development for the following conditions:   Alagille syndrome (ALGS) Progressive familial intrahepatic cholestasis (PFIC) and Biliary atresia (BA) It is important …

Why Jounce Therapeutics Stock is Outperforming Today

Jounce Therapeutics Jounce Therapeutics (JNCE) is a clinical-stage immunotherapy company developing therapies enabling the immune system to attack tumors and provide long-lasting benefits to patients through a biomarker-driven approach. Jounce has ongoing multiple development stage programs while simultaneously advancing additional early-stage assets from its robust discovery engine based on its Translational Science. Jounce Therapeutics Lead Products JTX-8064 – a LILRB2 (ILT4) receptor antagonist shown to …

Gain Therapeutics: A Biotech with Promising Treatments for Neurodegenerative Diseases and a Note from Prohost Biotech

Gain Therapeutics Inc in the News Gain Therapeutics, Inc. (GANX) announced today topline data from its  study conducted at the University of Maryland School of Medicine (UMSOM). The study, evaluating two lead Structurally Targeted Allosteric Regulators (STARs) compounds – GT-02287 and GT-02329 – for the treatment of Gaucher and GBA1 Parkinson’s Disease, demonstrated positive effects on all tested phenotypes. From Gain Therapeutics Inc and Others …

The U.S. FDA Accepts Exelixis sNDA of CABOMETYX® for Priority Review

Exelixis sNDA Accepted by the US FDA for CABOMETYX® The U.S. Food and Drug Administration (FDA) accepted Exelixis (EXEL) supplemental New Drug Application (sNDA) for CABOMETYX ® (cabozantinib) as a treatment for patients 12 years and older with differentiated thyroid cancer (DTC) who have progressed following prior therapy and are radioactive iodine-refractory (if radioactive iodine is appropriate). The FDA granted Priority Review designation and assigned …

Encouraging News from Hoth Therapeutics and Kintor Pharmaceutical Ltd About Treating Acne and Alopecia

Hoth Therapeutics Hoth Therapeutics (HOTH) announced that its product, HT-003, has yielded positive results in an in vivo acne therapeutic model. The model showed that HT-003 reduces the expression of toll-like receptor 2 (TLR2), which happens to be considered one of the most critical pathways for the acne pathophysiology. The study demonstrated that HT-003 reduces the expression of numerous cytokines critical for acne pathophysiology that are relevant …

The FDA Approval of Biogen’s Alzheimer’s Disease Drug and How Cassava Sciences Alzheimer’s Disease Drug Differs

Biogen Product Adulelm Approved for Alzheimer’s Disease The latest news regarding Alzheimer’s disease is that of the FDA’s approval of Biogen Inc’s (BIIB) Alzheimer disease product Adulelm (aducanumab). Although the approval seemed to be great news for Biogen many analysts and researchers, in highly regarded scientific institutions and universities, called it controversial. The FDA advisory committee has voted almost unanimously against approving Adulelm (aducanumab) for …

It’s All About Common Sense: Intellia Therapeutics

The Nonsensical Downgrading of Development-Stage Firms Like Intellia Therapeutics It makes no sense to downgrade a development-stage firm such as CRiSPR gene editing IntelliaTherapeutics (NTLA) when only based on stopping short of attaining analysts’ expectations with regard to revenues and incomes. Development-stage firms yet to have products on the market to generate money, contrarily, serious development-stage firms spend millions to realize their goals and put …

The Reasons for the Immunome, Inc Stock Rally

Immunome, Inc. Immunome, Inc (IMNM) announced today that its discovery engine has isolated potent antibodies capable of neutralizing several SARS-CoV-2 (the virus that causes COVID-19) variants, including the South African Variant (B.1.351), in pseudovirus testing.  This effort is part of the company’s ongoing program to develop a cocktail of antibodies targeting spike and non-spike proteins that can serve as prophylaxis or treatment for COVID-19. Immunome’s …

News About Reata Pharmaceuticals

Reata Pharmaceuticals The Positive News  Prohost Biotech’s interest in Reata Pharmaceuticals (RETA) started when we recognized and appreciated the firm’s goals and its scientific capability. Reata Pharmaceuticals’ goal is discovering molecular pathways that regulate cellular metabolism, inflammation and response to stress injury; hence, treat devastating diseases that have yet to find treatments. Our interest increased with the knowledge that it has already identified new entity …

A New COVID-19 Vaccine is Showing Successful Results. See Also: More Details About the Effective COVID-19 Vaccines

COVID-19 Vaccine Updates Pfizer’s (PFE)/BioNTech’s (BNTX) and Moderna’s (MRNA) COVID-19 vaccines have demonstrated safety at around 95% efficacy.   AstraZeneca (AZN) and Oxford University announced today that their COVID-19 vaccine was 90% effective in preventing infections. The efficacy average, however, was 70%, leading the stock to travel south rather than north.     Regardless of the efficacy differences AstraZeneca stated that it would immediately prepare …

SARS-CoV-2 Virus vs The President of the United States

President Trump, the First Lady and COVID-19 Indeed, the complicated, nasty SARS-CoV-2 virus managed to infect President Trump and the First Lady when we were expecting a vaccine to soon be ready to protect the country and the world from COVID-19. The president’s physicians did not treat the him with any of the investigational vaccines in late-phase trials; vaccines being developed by: Moderna (MRNA), Novavax (NVAX) and …

Sorrento Therapeutics Releases Preclinical Data from STI-1499 and STI-2020 Demonstrating Potent Neutralizing Antibodies Against SARS-CoV-2

Sorrento Therapeutics Preclinical Data of Neutralizing Antibodies Against SARS-CoV-2 In preclinical studies, both STI-1499 and STI-2020 demonstrated potent neutralizing activity against SARS-CoV-2 virus isolates, including the emerging Spike D614G variant virus. Both STI-1499 and STI-2020 demonstrated protective activities against SARS-CoV-2 infection in Syrian golden hamsters. At day 5, STI-2020 at 500 µg reduced virus load in hamster lungs to undetectable levels in 100% of animals …

Agenus: Could It Be a Resurrection? See Also: Prohost Performing Stocks

Agenus Announced Data from Phase 2 Trials of Balstilimab Agenus (AGEN) immuno-oncology company announced that data from two Phase 2 trials of balstilimab alone and in combination with zalifrelimab will be orally presented in at the upcoming European Society of Medical Oncology (ESMO) Conference on September 18, 2020.  The data will be presented by Dr. David O’Malley, Professor of Obstetrics and Gynecology at The Ohio State University College of Medicine and …

What’s Going on with Gene Therapy?

Recent Gene Therapy News On August 20, 2020 Audentes Therapeutics, which was taken over by Astellas (ALPMY) for over $3 billion, announced that a third patient has passed away in a clinical trial evaluating its gene therapy product AT132 for the treatment of the life-threatening neuromuscular X-linked Myotubular Myopathy (XLMTM). The neuromuscular disease is characterized by extreme muscle weakness, respiratory failure and early death. Preliminary …

The FDA’s Complete Response Letters, Creating Investment Opportunities?

Yesterday, under Today’s Highlights, we posted that the U.S. FDA issued a Complete Response Letter (CRL) to Gilead Sciences (GILD) with regard to the New Drug Application (NDA) for filgotinib – the investigational treatment for moderately to severely active rheumatoid arthritis (RA), in collaboration with Galapagos (GLPG). The FDA requested data from the ongoing MANTA and MANTA-RAy studies before completing its review of the NDA. …

An Important Announcement from Sorrento Therapeutics

Sorrento Therapeutics Announcement Sorrento Therapeutics (SRNE) announced that it believes it has uncovered fraudulent attempts to manipulate the Company’s stock.  In a press release from August 12, 2020 Sorrento informed that, on August 11, 2020 it was reported that an organization calling itself “Hindenburg Research” published claims regarding one of Sorrento’s COVID-19 diagnostic products. The report is believed to include false and/or misleading statements for …

Monopar Therapeutics: A Plan for a Test that Predicts COVID-19 Patients Who Might Likely Develop Severe Respiratory Failure

A Predictive COVID-19 Test? COVID-19 infected people are not all affected to the same degree with regards to the severity of the disease complications. There is no doubt that a test that can predict which patients will be severely affected and which will not might save a lot of lives, money and unnecessary time spent in crowded hospitals.    Monopar Therapeutics in the NEWS  Monopar …

Alterity Therapeutics: Treating Neurodegenerative Diseases?

When a small firm’s stock price soars, and more than doubles, curiosity pushes us to investigate.    Alterity Therapeutics Yesterday the stock soared for a firm called Alterity Therapeutics (ATHE) closing at $3.43 UP $2.08. We found that this firm’s market cap is $3.72 billion which boosted our curiosity to learn more about the nature of the news that rallied the stock and the firm’s business.       …

Edesa Biotech Stock Price Soared. Will It Continue to Rise?

Edesa Biotech Filed an IND for EB05 Edesa Biotech (EDSA), a clinical-stage biopharmaceutical company, has filed an investigational new drug (IND) application with the U.S. FDA for the initiation of a Phase 2/3 clinical study of its investigational drug EB05. Edesa has recently received expedited approval to begin the Phase 2/3 study in Canada and is seeking government grants to accelerate site selection and initiate …